Discoveries · Cambridge and Rahway
Moderna and Merck report positive Phase 3 trial results for personalized mRNA melanoma vaccine
Moderna and Merck announced that their individualized mRNA vaccine intismeran autogene significantly reduced recurrence and metastasis in 1,137 high-risk melanoma patients when combined with Keytruda.
AI text based on reports by Washington Post, La Razón, RTBF and other publishers. Changed . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
In the 1,137-patient Interpath-001 trial, combining intismeran autogene with Keytruda significantly improved recurrence-free survival and reduced metastasis compared to Keytruda alone.
The vaccine targets up to 34 patient-specific tumor neoantigens identified through genomic sequencing, with custom manufacturing completed in six weeks.
Moderna shares gained 177% to close at $174.38, Merck rose 13%, and BioNTech increased nearly 22% following the clinical trial announcement.
Moderna, Merck, BioNTech, and Roche are evaluating mRNA vaccines in lung, kidney, bladder, colon, and pancreatic cancers with study readouts scheduled through 2031.
- 2027Moderna-Merck kidney cancer and BioNTech-Roche colon cancer trial results expected
- 2031BioNTech and Roche pancreatic cancer Phase 2 trial results expected
- 2035Barclays projects $3 billion in annual sales for intismeran autogene
Phase 3 clinical trial findings
Moderna and Merck announced that their experimental mRNA cancer vaccine, intismeran autogene, met its primary endpoint in the Phase 3 Interpath-001 trial. The study evaluated 1,137 patients with stage 2B to stage 4 melanoma who had previously undergone complete surgical removal of their tumors. Patients receiving the vaccine alongside Merck's immunotherapy drug Keytruda (pembrolizumab) showed a statistically significant improvement in recurrence-free survival and reduced metastasis compared to Keytruda alone. Two-thirds of participants received Keytruda and up to nine doses of intismeran autogene, while one-third received Keytruda alone. The companies plan to present detailed findings at an upcoming medical conference before seeking regulatory approval.
Moderna chief executive Stéphane Bancel noted the shift toward individualized mRNA treatments.
“These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.”
Personalized mRNA mechanism and safety
Intismeran autogene, previously known as V940 or mRNA-4157, functions as a personalized therapeutic vaccine. Following tumor surgery, scientists sequence the patient's cancer genome to identify mutational signatures. The mRNA vaccine trains the immune system to recognize up to 34 neoantigens found exclusively on mutated cancer cells, with production taking six weeks. Adding the vaccine caused no new severe side effects beyond known Keytruda toxicities. In a 2022 Phase 2 trial, the combination reduced melanoma recurrence or death by 44% compared to Keytruda alone.
Georgina Long, lead investigator of Interpath-001, described the significance for postsurgical melanoma care.
“Today's results represent a milestone for the adjuvant treatment of melanoma. This is the first Phase 3 study showing that intismeran, a treatment designed from the unique mutational genetic footprint of each patient's tumor, administered in combination with pembrolizumab, can reduce the risk of recurrence or death in melanoma patients.”
Financial reaction and clinical pipeline
Following the announcement, Moderna shares gained 177% to close at $174.38 on Wednesday, while Merck rose 13% and BioNTech gained nearly 22%. Keytruda generated over $30 billion in revenue for Merck last year, with patents expiring near the end of the decade. Barclays estimates intismeran could generate $3 billion in annual sales by 2035, with a potential 2027 market launch. Moderna and Merck are conducting additional trials in lung, kidney, bladder, and pancreatic cancers. BioNTech and Roche are evaluating autogene cevumeran in colon and pancreatic trials with readouts expected in 2027 and 2031.
Mass General Brigham Cancer Institute melanoma director Ryan Sullivan noted the broader impact on cancer research.
“It is a big deal for the field in general. With this positive study, there is hope (and likely investment to follow) that these approaches may change the way we treat cancer more broadly.”
Ask about this text
Sources and context
- Washington PostOpinion | The cancer vaccine interrupts a technology backlash
- La RazónAvance histórico contra el cáncer de piel: una vacuna personalizada reduce el riesgo de recaída y muerte
- RTBFCancer de la peau : Moderna et Merck annoncent des résultats encourageants pour un vaccin - RTBF Actus
- GizmodoModerna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer
- Stéphane Bancel
- Chief executive officer of Moderna
- Georgina Long
- Lead investigator of the Interpath-001 trial and melanoma researcher
- Ryan Sullivan
- Director of the Center for Melanoma at Mass General Brigham Cancer Institute
- Julie Gralow
- Chief medical officer of the American Society of Clinical Oncology
- Places
- Cambridge, United States, Naples
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar